Summary
Valkyrie Mix B 400, manufactured by Valkyrie Pharma, underwent independent analysis to validate its labeled claims and assess its sterility. This product, containing a blend of Testosterone Cypionate and Boldenone Undecylenate, was submitted by AnabolicLab.com for testing. The results revealed minor deviations from the labeled concentrations, with both compounds measuring slightly below their specified dosages. Sterility tests confirmed the absence of microbial contamination.
Detailed Report
Product Overview
- Manufacturer: Valkyrie Pharma
- Product Name: Mix B 400
- Batch Number: HGM9468
- Expiration Date: November 2018
- Delivery Method: Injectable
Sample Acquisition and Testing
- Test Report Number: C 67068
- Testing Ordered: 28 February 2018
- Sample Received: 28 February 2018
- Analysis Conducted By: SIMEC AG
- Product Submitted By: AnabolicLab.com
- Analysis Paid For By: AnabolicLab.com
Testing Results
| Compound | Specification (Label Claim) | Measured Concentration | Accuracy | Variance | Compliance |
|---|---|---|---|---|---|
| Testosterone Cypionate | 200 mg/ml | 186.8 mg/ml | 93.40% | -6.60% | Yes |
| Boldenone Undecylenate | 200 mg/ml | 174.4 mg/ml | 87.20% | -12.80% | Yes |
| Microbiological Testing | Result | Specification |
|---|---|---|
| TAMC | <1 KBE/ml | Complies |
| TYMC | <1 KBE/ml | Complies |
Evaluation of Independent Testing
The analysis of Valkyrie Mix B 400 indicates that both active ingredients fall slightly below the labeled concentrations, with Boldenone Undecylenate showing a more notable deviation. Despite this, the product remains within an acceptable range of accuracy. The absence of microbiological contamination confirms its sterility and safety for use. These results pertain to the tested batch only, and further independent testing is recommended to evaluate consistency across other batches.
Conclusion
Valkyrie Mix B 400 demonstrates reasonable adherence to its labeled claims, with Testosterone Cypionate and Boldenone Undecylenate measuring at 93.40% and 87.20% of their specified concentrations, respectively. The product’s sterility was confirmed, highlighting its microbiological safety. However, minor inconsistencies in dosages suggest that additional testing is warranted to ensure uniformity across production batches.
Disclaimer
This report is published for educational and harm reduction purposes. The results apply exclusively to the tested batch and may not represent other batches of the same product. Readers are encouraged to cross-reference these findings with independent third-party testing for a more comprehensive assessment.
Discuss the Valkyrie Pharmaceutical Mix B 400 lab test results on the AnabolicLab Forum.
(The following images are photographs of the actual product that was submitted for testing.)
